Biogen Inc. (BIT:1BIIB)

Market Cap	15.27B
Revenue (ttm)	9.35B
Net Income (ttm)	1.58B
Shares Out	n/a
EPS (ttm)	10.80
PE Ratio	9.68
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36
Average Volume	15
Open	105.10
Previous Close	104.05
Day's Range	103.00 - 105.10
52-Week Range	101.40 - 220.70
Beta	n/a
RSI	22.23
Earnings Date	May 1, 2025

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1978
• Employees: 7,605
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1BIIB

Financial Performance

In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.

Financial numbers in USD